Kynamro approved to treat inherited cholesterol disorder
US FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder – Kynamro – mipomersen sodium – injection approved as an addition to lipid-lowering medications and diet to treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemia (HoFH). Kynamro is approved by the U.S. Food and Drug Administration.